Abstract Details

Title Safety and tolerability of lacosamide monotherapy in elderly: A subgroup analysis from lacosamide trials in diabetic neuropathic pain

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) (-)

Poster/Presentation
Number 239

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
R E. Faught, Jr., MD, FAAN (Emory University) PRESENTER	Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Life Science. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Gideon, Essary, Tardio and Carter PLC, Nashville TN TN law firm. Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Friedman Dazio and Zulanas Law Firm Birmingham AL. The institution of Dr. Faught has received research support from UCB Pharma. The institution of Dr. Faught has received research support from Cognizance.
Marc De Backer, MD, FBCPM, MBA	No disclosure on file
	No disclosure on file
Frank Tennigkeit, PhD (UCB Biosciences GmbH)	Dr. Tennigkeit has received personal compensation for serving as an employee of UCB Biosciences. Dr. Tennigkeit has stock in UCB Biosciences.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Konrad J. Werhahn, MD (HCPS, NINDS, NIH)	No disclosure on file
	No disclosure on file

��ɫ��